Navigation Links
PDL BioPharma Receives Letter from Genentech Relating to European Patents
Date:8/13/2010

INCLINE VILLAGE, Nev., Aug. 13 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-Looking Statements

This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
  • The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
  • The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
  • Changes in any of the other assumptions on which PDL's projected royalty revenues are based;
  • The outcome of pending litigation or disputes; and
  • The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" section of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CeNeRx BioPharma Completes $13 Million Series C Financing
2. Almac Launch Biomarkers for Biopharma
3. Health Outcomes Data Essential to Biopharmaceutical Sales Process
4. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
5. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
6. Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences
7. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
8. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
9. PDL BioPharma To Hold Annual Meeting of Stockholders on June 9, 2010
10. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
11. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly ... announced plans to invest $850 million in its ... facilities across its U.S. enterprise, including research laboratories, ... investments are being driven by demand for Lilly ... potential medicines in development targeting cancer, pain, diabetes ...
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, ... advanced medical technology for non-invasive surgery, announced today ... System for treatment of uterine fibroids throughout the ... had received approval from the US Food and ... the Mirabilis System in the United States.  The ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... ... 2017 , ... “Finding Christ Through Social Media: Year One ... the writer’s path toward true communion with God. “Finding Christ Through Social Media: ... creation of published author Lea Michelle Johnson, a follower of Christ, wife and ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of ... people of God in congregations across the United States. “The Communion of ... in 1964 who has served congregations in seven states throughout his long career ...
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
Breaking Medicine News(10 mins):